Takeda licenses exclusive rights to ImmunoGen's ADC technology
Executive Summary
Takeda Pharmaceutical Co. Ltd., through its Takeda Oncology division (also known as Millennium Pharmaceuticals Inc.), licensed exclusive rights to use ImmunoGen Inc.’s antibody-drug conjugate (ADC) technology to develop targeted therapies against two undisclosed cancer targets. (Takeda has an option to apply the technology to a third target, for an additional fee.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice